



NEXEL Co., Ltd.  
55 Magokdong-ro, Seoul,  
07802 Republic of Korea

+82-2-2088-8886 T

+82-2-2088-8884 F

[support@nexel.co.kr](mailto:support@nexel.co.kr) E

[www.nexel.co.kr](http://www.nexel.co.kr) W

## CERTIFICATE OF ANALYSIS

<b>PRODUCT NAME</b>	Cardiosight®-S
<b>Catalog Number</b>	C-002
<b>Lot Number</b>	C2-0A2

- ▼ The Cardiosight®-S consists of a population of human induced pluripotent stem cell derived cardiomyocytes. NEXEL Co. Ltd. guarantees this product has passed the following test parameters while adhering to the Cardiosight®-S User Guide. Please keep in mind, electrophysiology measures will vary with plating conditions.

PARAMETER	RESULT
Purity / Identity	93.3 % Cardiomyocytes (+cTnT)
Cell Count & Viability	5.28 million cells (49.6 %)
Electrophysiology	
Beat rate (BPM)	37.69
FPD (FPDcF)	546 ms (468 ms)
Drug Response	
E4031 (FPDcF increase at 0.01 µM > 15%)	Pass
Nifedipine (FPDcF decrease at 0.1 µM > 30%)	Pass
Mexiletine (Spike amplitude decrease at 10 µM > 15%)	Pass
Sterility	Pass
Mycoplasma	Negative
Others	Negative

The signature below attests that the above tests were performed according to NEXEL SoP.

Quality Control Test by: Jieun An  Date: February 7<sup>th</sup>, 2022

The signature below attests that the production lot has been cleared for sales & distribution.

Approved for Sale by: Dong-Hun Woo  Date: February 7<sup>th</sup>, 2022